Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

BMJ open·2026
Same author

Reply to Therese Kang and Wee Loon Ong's Letter to the Editor re: Ragu Ratnakumaran, Douglas H. Brand, Archana Sasitharan, et al. Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study. Eur Urol 2026;89:71-9.

European urology·2026
Same author

Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

International journal of radiation oncology, biology, physics·2026
Same author

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

European urology oncology·2026

Related Experiment Videos

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate

Amar U Kishan1, Xiaoyan Wang2, Yilun Sun3

  • 1Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.

European Urology
|April 26, 2022
PubMed
Summary

For prostate cancer, increasing radiotherapy dose alone does not improve metastasis-free survival. Adding androgen deprivation therapy (ADT) significantly improves outcomes, with high-dose radiation plus long-term ADT being the optimal strategy.

Related Experiment Videos

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • The comparative efficacy of escalating radiotherapy (RT) doses and incorporating short-term or long-term androgen deprivation therapy (STADT or LTADT) for prostate cancer treatment remains unclear.
  • Optimizing treatment strategies is crucial for improving patient outcomes and reducing cancer recurrence.

Purpose of the Study:

  • To conduct a network meta-analysis (NMA) comparing the benefits of RT dose escalation with or without STADT or LTADT.
  • To identify the optimal treatment strategy for prostate cancer based on metastasis-free survival (MFS) and biochemical recurrence-free survival (BCRFS).

Main Methods:

  • An NMA of individual patient data from 13 multicenter randomized trials involving 11,862 patients.
  • Patients received low-dose RT (<74 Gy) or high-dose RT (≥74 Gy), with or without STADT or LTADT.
  • Frequentist and Bayesian NMAs were used to analyze MFS and BCRFS outcomes.

Main Results:

  • The addition of LTADT, followed by STADT, provided the greatest improvement in outcomes, irrespective of RT dose.
  • RT dose escalation alone or with ADT did not significantly improve MFS.
  • High-dose RT combined with LTADT emerged as the optimal strategy for both BCRFS and long-term outcomes.

Conclusions:

  • Conventionally escalated RT, with or without ADT, does not enhance MFS. However, adding STADT or LTADT to RT consistently improves MFS.
  • RT dose escalation shows potential for improving BCRFS, especially when combined with ADT, suggesting it may be an optimal strategy if delivered without compromising quality of life.